Fund IV was oversubscribed and will expand growth equity investments in the healthcare services, HCIT, B2B SaaS, and tech-enabled services sectors
Fulcrum Equity Partners, a growth equity firm investing in healthcare services, HCIT, B2B SaaS, and tech-enabled services, announced it has closed its fourth and largest fund to date, Fulcrum Growth Fund IV (“Fund IV”), which was oversubscribed with $275 million in committed capital.
Fulcrum’s existing investor base validated the firm’s thesis and approach with nearly 100% participation from institutional investors in prior funds and many investors increasing their allocations over previous commitments. New institutional investors and family offices also joined the firm’s longtime stable of C-level executives—a key element of Fulcrum’s strategic value-add since its founding in 2006.
Read More: Deloitte: Hastened by the Pandemic, Global Enterprises Increase Investments in Advanced Wireless
“As a team of seasoned entrepreneurs ourselves, we started the firm’s first fund by gaining the financial and operational support of like-minded executives who continue to invest and serve as a rich resource in diligence, market knowledge, connections, and board composition for our portfolio companies,” said Fulcrum Founding Partner Tom Greer. This experience and the firm’s resulting approach helped land Fulcrum on Inc. Magazine’s List of the Top 50 Founder Friendly Firms in 2020.
The Fulcrum team works alongside management to build the companies into scalable, professionally-run organizations, assisting in attracting talent, executing strategic initiatives, and implementing operational discipline. In 2020, two Fulcrum portfolio companies made the Inc. 500 and eight in total were listed on the Inc. 5000. With the ability to invest $4 to $25 million, Fulcrum can provide significant funding to drive growth initiatives, acquisitions, and shareholder liquidity. The firm has a history of leading multiple rounds of investments in its portfolio companies, including those in Fattmerchant, SaasOptics, Stratasan, and many others.
Read More: iShares Takes Steps to Lead Industry in Style Investing
Fulcrum typically invests east of the Rockies, partnering with strong founders building great companies in traditionally underserved markets. Fulcrum has three Fund IV investments to date—Kobiton, Proxsys Rx, and Kevel.
“The innovation emerging across the country promises an exciting path for Fund IV. Our team is looking for strong businesses with leadership teams who are ready for the next phase of growth with partners who can offer much more than capital,” said Founding Partner Jeff Muir.
Read More: Newlink Group Raises $300 Million In Funding From Leading Financial Institutions
